**Chapter 3**

*Acute Leukemias*

[30] Marcu A, Colita A, Radu LE, et al. Single-Center Experience With Epigenetic Treatment for Juvenile Myelomonocytic Leukemia. *Front Oncol*. 2020;10:484. Published 2020 Apr

9. doi:10.3389/fonc.2020.00484

[32] Kong G, Wunderlich M, Yang D, Ranheim EA, Young KH, Wang J, et al. Combined MEK and JAK inhibition abrogates murine myeloproliferative neoplasm. J Clin

Invest 2014;124(6):2762-73.

[33] Tasian SK, Casas JA, Posocco D, Gandre-Babbe S, Gagne AL, Liang G, et al. Mutation-specific signalling profiles and kinase inhibitor sensitivities of juvenile myelomonocytic leukemia revealed by induced pluripotent stem cells. Leukemia 2019;33(1):181-90.

[31] Sonia Meynier and Frédéric Rieux-Laucat, Blood Reviews, https://doi. org/10.1016/j.blre.2020.100652

**34**
